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Abstract
Introduction: In contrast to its role in breast cancer (BCa) initiation, estrogen signaling has a protective effect in
later stages, where estrogen receptor (ER)a loss associates with aggressive metastatic disease. We asked whether
the beneficial effect of estrogen signaling in late-stage BCa is attributable to the recently reported estrogen-
mediated antagonism of the pro-metastatic transcription factor Runx2.
Methods: MCF7/Rx2
dox breast cancer cells were engineered with a lentivirus expressing Runx2 in response to
doxycycline (dox). Cells treated with dox and/or estradiol (E2) were subjected to genome-wide expression profiling,
RT-qPCR analysis of specific genes, and Matrigel™ invasion assays. Knockdown of genes of interest was performed
using lentiviruses expressing appropriate shRNAs, either constitutively or in response to dox. Gene expression in
BCa tumors was investigated using a cohort of 557 patients compiled from publicly available datasets. Association
of gene expression with clinical metastasis was assessed by dichotomizing patients into those expressing genes of
interest at either high or low levels, and comparing the respective Kaplan-Meier curves of metastasis-free survival.
Results: Runx2 induced epithelial-mesenchymal transition (EMT) evidenced by acquisition of a fibroblastic
morphology, decreased expression of E-cadherin, increased expression of vimentin and invasiveness. Runx2
stimulated SNAI2 expression in a WNT- and transforming growth factor (TGF)b-dependent manner, and knockdown
of SNAI2 abrogated the pro-metastatic activities of Runx2. E2 antagonized the pro-metastatic activities of Runx2,
including SNAI2 upregulation. In primary BCa tumors, Runx2 activity, SNAI2 expression, and metastasis were
positively correlated, and SNAI2 expression was negatively correlated with ERa. However, the negative correlation
between SNAI2 and ERa in bone-seeking BCa cells was weaker than the respective negative correlation in tumors
seeking lung. Furthermore, the absence of ERa in primary tumors was associated with lung- and brain- but not
with bone metastasis, and tumor biopsies from bone metastatic sites displayed the unusual combination of high
Runx2/SNAI2 and high ERa expression.
Conclusions: E2 antagonizes Runx2-induced EMT and invasiveness of BCa cells, partly through attenuating expression
of SNAI2, a Runx2 target required for mediating its pro-metastatic property. That ERa loss promotes non-osseous
metastasis by unleashing Runx2/SNAI2 is supported by the negative correlation observed in corresponding tumors.
Unknown mechanisms in bone-seeking BCa allow high Runx2/SNAI2 expression despite high ERa level
Introduction
Metastasis of primary tumors to distant sites is a com-
plex process that involves a sequence of interdependent
events including intravasation, survival within the circu-
lation, extravasation, and colonization. Epithelial-
mesenchymal transition (EMT) has been strongly impli-
cated in metastasis [1,2]. During EMT, epithelial cells
dissociate from each other, in part due to loss of E-cad-
herin expression, upregulate mesenchymal markers,
acquire a fibroblast-like morphology, reorganize their
cytoskeleton, and become more motile and invasive
[1,2]. Several transcription factors, including members of
the SNAI family have been shown to promote EMT and
thus tumor dissemination [3-5]. Bone metastasis is a
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tinct gene signatures defining bone-seeking tumors
[6-9].
Prolonged exposure to estradiol (E2) is associated with
an increased risk of BCa [10-14]. The mechanisms
through which estrogens contribute to BCa initiation
and progression are complex and implicate estrogen
receptor (ER)-mediated genomic and nongenomic sig-
naling as well as the action of genotoxic estrogen meta-
bolites [12]. In contrast to E2-mediated carcinogenesis,
t h ep r e s e n c eo fE R a is a favorable prognostic marker
associated with less invasive tumors, and those negative
for ERa are more aggressive [15]. A randomized clinical
trial of postmenopausal women receiving equine estro-
gen treatment revealed a decrease in BCa incidence [16]
and low-dose estradiol treatment has been proposed as
a treatment modality for advanced ERa-positive BCa
that does not respond to aromatase inhibition [17].
Indeed, introduction of ERa into ERa-negative BCa
cells attenuated their pro-cancerous properties in vitro
[18-21]. Thus, anti-estrogen therapy for BCa patients,
while antagonizing the oncogenic properties of estro-
gens, may inadvertently result in loss of their anti-meta-
static property. Better understanding of mechanisms
underlying the beneficial role of estrogen signaling in
advanced disease may inform the development of novel
therapeutic approaches and improved treatment plans
for BCa patients.
Runx2 is a lineage-specific transcription factor with
crucial roles in both bone biology and carcinogenesis
[22-24]. During development Runx2 is involved in the
process of osteogenesis. Targeted disruption of Runx2 in
mice leads to failure of osteoblast differentiation and
bone formation [25,26], and Runx2 haploinsufficiency in
humans results in the skeletal disorder cleidocranial dys-
plasia, with a similar phenotype observed in Runx2 hap-
loinsufficient mice [25]. Although Runx proteins have
tumor suppressor properties [24], recent studies
assigned a role for Runx2 in promoting breast and pros-
tate cancer metastasis [27-32]. Thus, Runx2 and E2 sig-
naling play dual roles in BCa, with each functioning to
either promote or suppress tumor progression. The
mechanisms underlying these contrasting manifestations
in cancer are poorly understood.
We previously showed that in the presence of ligand,
ERa physically binds Runx2 and inhibits expression of
several Runx2 target genes [33]; our recent study
revealed that in MCF7 BCa cells E2 independently regu-
lated about half of the Runx2-responsive genes [34]. We
therefore hypothesized that gene(s) stimulated by Runx2
and inhibited by E2 may contribute to manifestations of
the pro-metastatic or tumor suppressor functions of
Runx2 and E2, respectively. Using a combination of tis-
sue culture modeling and bioinformatics analysis of
gene expression in BCa biopsies, we present evidence
suggesting that SNAI2/SLUG plays a role in mediating
the pro- and anti-metastatic effects of Runx2 and E2,
respectively.
Materials and methods
Cell culture assays and reagents
MCF7 and T47D BCa cells were obtained from the
American Type Culture Collection (Rockville, MD,
USA). MCF7/Rx2
dox cells, engineered to express Runx2
in response to doxycycline (dox) [34], were maintained
in Dulbecco’s modified Eagle’sm e d i u m( D M E M )c o n -
taining 10% fetal bovine serum (FBS) and 50 μg/ml
Hygromycin B (GIBCO, Carlsbad, CA). Data presented
herein were obtained from cells cultured in phenol red-
free DMEM containing 10% charcoal-stripped FBS
(Hyclone, South Logan, UT), 0.5 μg/ml dox (Calbio-
chem, San Diego, CA) and/or 10 nM E2 (Sigma, St
Louis, MO). For invasion assays, cells further engineered
to constitutively express luciferase were placed in Matri-
gel™-containing inserts (BD Biosciences, Bedford, MA)
and invasion was assessed based on luciferase activity in
cells that had crossed the membrane [30]. The Wnt
inhibitor ICG-001 was synthesized as previously
described [35]. Mouse monoclonal anti-SNAI2 and anti-
Runx2 antibodies were from Millipore (Billerica, MA)
and Invitrogen (Grand Island, NY), respectively. Anti-
TGF-b type I receptor (TGFBRI) blocking antibody (sc-
398) and negative control antibody (sc-2027) were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Real-time quantitative RT-qPCR analysis
Total RNA was extracted using Aurum™ Total RNA
Mini-Kit (BioRad, Hercules, CA) and cDNA was synthe-
sized with iScript Reverse Transcription Kit (BioRad).
RT-qPCR was carried out in triplicate using iQ™ SYBR
Green Supermix (BioRad) and a CFX96 qPCR machine
(BioRad). All transcript levels were normalized to that of
GAPDH. Primers used for PCR are listed in Additional
file 1.
Gene silencing
T47D/shRx2
dox cells, conditionally expressing shRNA to
silence Runx2 in response to dox, were previously
described [36]. For SNAI2 silencing, specific Mission-
shRNA lentiviral plasmids (SHCLNG) and a negative
control shRNA plasmid (SHC002) were purchased from
Sigma and packaged as described [30] using HEK293T
cells and the helper plasmids pMD.G1 and pCMV.
R8.91. Viral particles were used for transduction of
MCF7/Rx2
dox cells followed by selection with 1 μg/ml
Puromycin (Invitrogen, Carlsbad, CA). Of five shRNAs
tested, two were found to reduce SNAI2 expression by
> 75% and the corresponding cells were propagated as
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are listed in Additional file 1.
Data mining
For primary analysis of gene expression profiles in clini-
cal samples, we compiled microarray data from 557 BCa
patients by combining three Gene Expression Omnibus
(GEO) datasets, GSE2034, GSE2603 and GSE12276
[37-39]. These datasets were generated using Affymetrix
chips HG-U133A (GSE2034 and GSE2603) and HG-
U133plus2 (GSE12276). The Affymetrix CEL files were
downloaded into Partek, normalized using the RMA
(Robust Multiarray Averaging) method and filtered for
common probes using interplatform comparison. The
data were standardized by centering and scaling and
patients were dichotomized into low and high expres-
sing groups with regard to the indicated genes of inter-
est. Dichotomizing of the tumors according to the ESR1
Affymetrix probe ‘205225_at’ was consistent with the
histological definition of their ER status in 329 of 368
cases (89.4%) for which pathological annotation was
available, and with the molecular definition of their ER
status in 177 of 189 cases (93.7%) where it was based on
different processing of the microarray data [9]. Clinical
features, including hormonal status, metastasis-free sur-
vival time and sites of metastasis, have been compiled
from the supplementary information of the published
studies [9,37]. For each patient, metastasis-free survival
was defined as the time interval between surgery and
the diagnosis of metastasis. Only tumors with unambig-
uous information about sites of metastasis were included
in the cohort. For metastatic tissue analyses we used the
microarray data from 58 archival human breast carci-
noma metastasis specimens deposited into GEO under
accession number GSE14020 [9]. Because all the data
were from publicly available resources, we did not
require ethical approval to carry out this study.
Survival analyses and hierarchical clustering were per-
formed using Partek Genomics Suite 6.6 and the corre-
lation study was performed using Graphpad. Functional
annotation of gene groups was performed using both
the web-based Database for Annotation, Visualization,
and Integrated Discovery (DAVID) system [40] and the
Ingenuity Pathways Analysis (IPA™) package.
Results
Metastasis-related genes in BCa cells are stimulated by
Runx2 and inhibited by E2
A recent study with prostate cancer cells and a dox-
inducible lentiviral system identified a Runx2-regulated
metastasis-related gene network [30]. We used the same
system to conditionally express Runx2 in the ER-posi-
tive/Runx2-negative MCF7 BCa cells, and determined
the genes that were responsive to Runx2 (N = 1,081) or
E2 (N = 2,435) [34]. Interestingly, almost half of the
Runx2 responsive genes were also E2-responsive (N =
530) and these ‘common’ genes are listed in Additional
file 2 along with their level of responsiveness to Runx2
and E2. Functional computational analysis linked these
530 ‘common’ genes to angiogenesis and cell movement
(Table 1), suggesting their importance in tumor metas-
tasis. A literature survey for the top ten ‘common’ genes
(Table 2) identified three – SNAI2, S100A9 and
CXCL12, which have been implicated in cell motility
and BCa metastasis [4,41,42]. Moreover, SNAI2 and
S100A9 were downregulated by E2. These genes may
contribute to the pro- and anti-invasive properties of
Runx2 and E2, respectively.
Functional link between Runx2, E2 and SNAI2 in BCa
Of the top ‘common’ genes, SNAI2 was of particular
interest not only because its expression was the second
most stimulated by Runx2 (6.6-fold) but also because it
was strongly inhibited by E2 (-3.4-fold) (Table 2).
Furthermore, the SNAI family of transcription factors is
known to play a role in EMT [3-5]. By Western blot
analysis, SNAI2 protein was detected in MCF7/Rx2
dox
cells only after the induction of Runx2 (Figure 1A).
Additional support for the regulation of SNAI2 by
Runx2 was provided by RT-qPCR analysis of other cell
types, namely C4-2B/Rx2
dox prostate cancer cells, in
which SNAI2 was stimulated by dox-induced Runx2
(Figure 1B), and T47D/shRx2
dox BCa cells, in which
SNAI2 expression was inhibited after dox-induced
shRNA-mediated silencing of endogenous Runx2 (Figure
1C). We then sought evidence for the positive and nega-
tive regulation of SNAI2 by Runx2 and ERa, respec-
tively, in BCa tumors. We compiled a cohort of 557
Table 1 Functional Annotation Clustering of Genes
Independently Regulated by Runx2 and E2 in MCF7/
Rx2
dox Cells
Category Term P value
Annotation
Cluster 1
Enrichment Score: 4.50
GOTERM_BP_FAT GO:0001944~vasculature development 2.22E-05
GOTERM_BP_FAT GO:0048514~blood vessel
morphogenesis
2.72E-05
GOTERM_BP_FAT GO:0001568~blood vessel development 5.40E-05
Annotation
Cluster 2
Enrichment Score: 4.48
GOTERM_BP_FAT GO:0016477~cell migration 2.55E-05
GOTERM_BP_FAT GO:0048870~cell motility 3.77E-05
GOTERM_BP_FAT GO:0051674~localization of cell 3.77E-05
DAVID Functional Clustering brings the similar, redundant, and heterogeneous
annotation contents from the same or different resources into annotation
groups. Enrichment Score ranks the significance of biological functions and
measured as geometric mean of member’s P-values in a corresponding
annotation cluster. Shown are the top two annotation clusters for the 530
‘common’ genes, those independently regulated by Runx2 and E2.
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GSE2034, GSE2603 and GSE12276 [37-39] and initially
investigated the correlation between SNAI2 expression
and a Runx2 metagene, the latter defined as the average
normalized expression of all genes that Runx2 stimu-
lated by ≥ 2-fold in the MCF7/Rx2
dox system (except
SNAI2 itself). As shown in Figure 1D, there was a posi-
tive correlation between expression of SNAI2 and the
Runx2 metagene across the 557 BCa patient cohort. On
the other hand, SNAI2 expression in the clinical speci-
mens was negatively correlated with ERa/ESR1: tumors
with low ESR1 expression (mostly histologically ER-
negative) had significantly more SNAI2 transcripts than
those with high ESR1 expression (Figure 1E), and the
latter (mostly ER-positive tumors) exhibited a negative
correlation between ESR1 and SNAI2 expression (Figure
1F). These data suggest that SNAI2 is stimulated by
Runx2 and inhibited by E2 not only in the MCF7/
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Figure 1 Relationships between Runx2, E2 and SNAI2 in BCa. (A) Runx2 was induced by treating MCF7/Rx2
dox BCa cells with dox for 48
hours, and the effect on SNAI2 protein level was assessed by Western blot analysis of nuclear extracts. (B-C) Runx2 was either induced for 48
hours by dox treatment of C4-2B/Rx2
dox PCa cells (B) or silenced by 48-hour dox treatment of T47D/shRx2
dox BCa cells (C), and the effects on
SNAI2 expression were analyzed by RT-qPCR. Western blot analysis of whole cell extracts confirms the respective dox-induced induction and
silencing of Runx2. (D) Correlation between SNAI2 mRNA and Runx2 activity in a cohort of 557 BCa tumors. Runx2 activity was defined as the
average normalized expression of genes that Runx2 stimulated by ≥ 2 fold in the MCF7/Rx2
dox cell culture model, except SNAI2 itself. (E)
Expression of SNAI2 mRNA in the same cohort, comparing tumors with high versus low ESR1/ERa levels. Asterisk (*) indicate statistically
significant difference (P < 0.05) based on unpaired t-test with Welch correction of the log2-transformation of the signal intensities. (F) Analysis of
the tumors with high ESR1/ERa expression for correlation between ESR1/ERa and SNAI2. The patient cohort for D-F was compiled from the
publicly available GEO datasets GSE2034, GSE2603 and GSE12276 [37-39]. BCa, breast cancer; dox, doxycycline; E2, estradiol; ESR1/ER, estrogen
receptor alpha; GEO, Gene Expression Omnibus; PCa, prostate cancer; RT-qPCR; reverse transcription - quantitative polymerase chain reaction;
Runx2, runt related transcription factor 2; SNAI2, snail homolog 2.
Table 2 Genes Independently Regulated by Runx2 and E2
in MCF7/Rx2
dox Cells
Genes dox (Runx2)/Control E2/Control
fold change p value fold change P value
RIS1 6.81 5.94E-08 1.53 7.19E-04
SNAI2 6.59 1.87E-07 -3.38 4.82E-06
SGK 4.77 1.91E-09 4.81 3.60E-09
C20orf114 4.77 1.87E-07 -1.52 6.72E-04
C10orf81 4.61 2.20E-07 -2.16 2.43E-05
MGP 4.52 1.37E-07 5.59 1.21E-07
CRISPLD2 4.49 7.78E-08 -1.96 1.72E-05
S100A9 3.98 4.19E-06 -1.59 3.28E-03
PLAC8 3.83 9.95E-07 -1.60 7.39E-04
CXCL12 3.67 1.99E-07 3.58 4.32E-07
Of 530 ‘Common Genes’ (Supplemental Table 2), the ten most strongly
stimulated by Runx2 are listed along with fold expression change in response
to Runx2 and E2, as well as the corresponding p values. Negative values
indicate repression.
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dox model (Table 2), but also in other cell lines, as
well as in BCa tumors.
E2 antagonizes Runx2-induced EMT and invasiveness in
vitro
Because SNAI2 has been implicated in EMT and in the
invasive metastatic behavior of breast and other cancer
cells [3,4] we employed the MCF7/Rx2
dox culture system
to test the hypotheses that Runx2 induces and E2 antag-
onizes EMT and invasiveness, and that SNAI2 plays a
role in these processes. We initially measured by RT-
qPCR the expression levels of EMT and motility-related
genes in MCF7/Rx2
dox cells treated with dox, E2, or
both together. Consistent with the microarray results
(Table 2), SNAI2 expression was increased by 9.7 fold
and repressed by 4.6 fold in response to 48-hour
treatment with dox and E2, respectively (Figure 2A).
The mRNA for another well-established marker of moti-
lity and invasion, S100A4 [43,44], was also stimulated by
Runx2. Although E2 did not affect basal S100A4 expres-
sion, it completely blocked the Runx2-mediated induc-
tion (Figure 2A). Despite the stimulation of SNAI2 and
S100A4 by Runx2, these changes in gene expression
were not accompanied by either noticeable morphologi-
cal changes (data not shown) or a decrease in the
epithelial marker E-cadherin (CDH1) or an increase in
the mesenchymal marker vimentin (VIM) (Figure 2A).
Taken together these results suggest that induction of
Runx2 for two days at best initiated partial EMT in
MCF7 cells.
We further assessed expression of EMT and motility-
related genes seven days after Runx2 induction in
Runx2 (dox) 
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Figure 2 E2 antagonizes Runx2-induced EMT markers and invasiveness of MCF7/Rx2
dox BCa cells.( A) MCF7/Rx2
dox cells were maintained
for two days in medium supplemented with CSS and then treated for two days with either vehicle control (C), dox (D), E2 (E), or both
stimulants (DE), followed by RT-qPCR analysis of SNAI2, S100A4, vimentin (VIM) and E-cadherin (CDH1) mRNAs. (B) Relative expression of the
same marker genes after treatment as in A for seven days. (C) Phase-contrast images of MCF7/Rx2
dox cells after seven days of treatments as
indicated. (D) MCF7/Rx2
dox cells transduced with lentiviruses constitutively expressing firefly luciferase were placed in BD Biocoat™ Transwell
inserts with Matrigel™ and treated for 24 hours as indicated. Luciferase activity in cells that invaded through the Matrigel™ membrane is
presented relative to the average control value (Mean ± SD; n =3 ;* * P < 0.01). CSS, charcoal stripped serum; dox, doxycycline; E2, estradiol; EMT,
epithelial-mesenchymal transition; RT-qPCR; reverse transcription - quantitative polymerase chain reaction; Runx2, runt related transcription factor
2; S100A4, S100 calcium binding protein A4; SNAI2, snail homolog 2.
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dox cells. As shown in Figure 2B, this pro-
longed induction resulted in a more complete EMT. Not
only were SNAI2 and S100A4 stimulated, CDH1 was
downregulated and VIM was upregulated. Finally, micro-
scopic examination of cultures seven days after Runx2
induction demonstrated a fibroblast-like and scattered
morphology as compared to control cultures (Figure 2C).
Thus, the partial EMT indicated by increased SNAI2 and
S100A4 expression on day 2 (Figure 2A) developed into a
more comprehensive EMT phenotype by day 7. More
importantly, E2 significantly antagonized most of the
Runx2-induced EMT characteristics. It blunted the
Runx2-mediated effects on SNAI2 and CDH1 expression,
and attenuated the Runx2-mediated effects on the
expression of VIM and S100A4 (Figure 2B), as well as its
effects on cell morphology (Figure 2C).
Finally, we measured the effects of Runx2 and E2 on
BCa cell invasiveness. MCF7/Rx2
dox cells were trans-
duced with lentiviruses constitutively expressing firefly
luciferase and placed on top of Matrigel™ membranes
within BD Biocoat™ inserts. Luciferase activity asso-
ciated with cells that had crossed the membrane, a mea-
sure of invasiveness [30], was two-fold higher in
cultures treated with dox to induce Runx2 as compared
to controls, while co-treatment with E2 attenuated the
Runx2-mediated invasiveness (Figure 2D). E2 alone had
little, if any, effect on MCF7/Rx2
dox cell invasiveness
through Matrigel™.
SNAI2 plays a critical role in Runx2-mediated MCF7 cell
invasion
We next tested the hypothesis that SNAI2 was required
for Runx2-mediated EMT and invasion in MCF7/Rx2
dox
B C ac e l l s .T ot h i se n d ,M C F 7 / R x 2
dox BCa cells were
transduced with lentiviruses expressing two independent
shRNAs, sh1-SNAI2 and sh2-SNAI2, which target dis-
tinct regions of the SNAI2 transcript. Both shRNAs
reduced SNAI2 mRNA levels by > 75% compared to
cells expressing a control shRNA (Figure 3A). Cells
were then treated with dox and/or E2, followed by RT-
qPCR analysis of EMT markers and Matrigel™ invasion
assays. Remarkably, SNAI2 knockdown by RNA interfer-
ence abolished the Runx2-mediated decrease in CDH1
mRNA and increase in VIM mRNA, implicating SNAI2
in Runx2-mediated EMT (Figure 3B). Although SNAI2
silencing did not antagonize the stimulation of S100A4
by Runx2 (Figure 3B), it completely abrogated the ability
of Runx2 to increase MCF7 cell invasion through Matri-
gel™ (Figure 3C).
WNT and TGFb signaling are required for Runx2-mediated
stimulation of SNAI2 expression
EMT is regulated by various signal transduction path-
ways including WNT and TGFb [45,46], and IPA™
analysis of the 530 ‘common’ genes for representation of
developmental and growth factor signaling pathways
indicated enrichment of WNT/b-catenin pathway-
related genes (Figure 4A). Both the WNT and TGFb
pathways have been also implicated in the regulation of
SNAI2 expression [47,48]. Given that SNAI2 was
required for Runx2-mediated EMT and invasiveness, we
asked whether Runx2-mediated stimulation of SNAI2
expression involved WNT and TGFb signaling path-
ways. To this end, MCF7/Rx2
dox cells were treated with
dox, E2 or both, along with inhibitors of either WNT or
TGFb signaling. WNT signaling was inhibited by using
ICG-001, a small molecule that interferes with the
recruitment of CAAT-enhancer binding protein (CBP)
to b-catenin/LEF/TCF complexes [35]. For TGFb block-
ade, we used neutralizing antibodies against TGFBR1.
A ss h o w ni nF i g u r e4 B ,b o t hI C G - 0 0 1a n dt h ea n t i -
TGFBR1 antibody attenuated Runx2-induced SNAI2
expression. Interestingly, attenuation of the Runx2
response with either ICG-001 or the anti-TGFBR1 anti-
bodies was no longer observed in cells co-treated with
both dox and E2 (Figure 4B). Co-blockade of the WNT
and TGFb pathways was as effective as blocking each
separately (data not shown). Thus, inhibition of either
WNT or TGFb signaling, or the presence of E2, sup-
pressed Runx2-stimulated SNAI2 expression in MCF7
BCa cells. Neither WNT nor TGFb interference affected
Runx2-stimulated SNAI2 expression in the presence of
E2. These results suggest that the WNT and TGFb
blockade may have targeted the same pathways by
which E2 antagonizes Runx2 in BCa cells.
Negative association of SNAI2 with metastasis-free
survival in BCa patients
We next determined the association between SNAI2
expression level and clinical BCa progression by con-
structing Kaplan-Meier curves for overall or site-speci-
fic metastasis-free survival of tumors expressing either
h i g ho rl o wl e v e l so fS N A I 2 .O ft h e5 5 7p a t i e n t sc o m -
piled from the publicly available datasets GSE2034,
GSE2603 and GSE12276 [37-39], 288 (52%) relapsed,
with 184, 28 and 76 developing bone, brain and lung
metastasis, respectively [38,39]. In cases of metastasis
to multiple organs, each of the corresponding sites was
included in the analysis. Overall, tumors expressing
SNAI2 at high levels were more likely to relapse than
those with low SNAI2 expression (Figure 5A-D).
Accordingly, tumors which did not metastasize were
mostly SNAI2
low (Figure 5M). The association between
SNAI2 expression and metastasis was particularly
strong for bone (P = 4.04E-010) (Figure 5D). These
results suggest that high expression of SNAI2 in BCa
primes tumors for metastasis in general and bone
metastasis in particular.
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bone-seeking BCa tumors
Suppression of SNAI2 expression in BCa cells by E2
(Figure 2A) may be related to the protective effect of
ERa against metastasis. Indeed, consistent with previous
reports [15,17-21], tumors with high ESR1 expression
were less likely to metastasize in our cohort, particularly
during the initial 20 to 40 months after surgery (Figure
5E). Analysis of the association between ESR1 expres-
sion and metastasis to specific sites, however, revealed
an interesting exception. Whereas high ESR1 expression
was negatively correlated with lung and brain metastasis
(Figure 5F-G), it positively correlated with bone metas-
tasis (Figure 5H). Thus, unleashing SNAI2 gene
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Figure 3 SNAI2 is required for Runx2-mediated EMT.( A) RT-qPCR analysis of SNAI2 mRNA in MCF7/Rx2
dox cells transduced with a control
(sh-Neg) or each of two independent SNAI2 shRNA lentiviruses. (B-C), MCF7/Rx2
dox cells transduced with sh1-SNAI2, sh2-SNAI2, or the negative
control virus were treated with vehicle control (C), dox (D), E2 (E), or both stimulants (DE). The effects of SNAI2 knockdown on expression of the
indicated EMT markers were assessed by RT-qPCR after seven days and the effects on invasion were assessed using Matrigel™-containing BD
Biocoat™ Transwells as in Figure 2D, except dox treatment was initiated 6 hours prior to placing the cells in the transwell chambers. **, P <
0.01; ***, P < 0.005. Dox, doxycycline; EMT, epithelial-mesenchymal transition; E2, estradiol; RT-qPCR, reverse transcription - quantitative
polymerase chain reaction; Runx2, runt related transcription factor 2; SNAI2, snail homolog.
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Page 7 of 13expression by loss of ERa is a plausible mechanism pro-
moting metastasis in general; however, high expression
of SNAI2 in cells that metastasize to bone occurs
despite high ESR1 expression. Furthermore, SNAI2
expression was associated with lung and brain metasta-
sis only for tumors expressing low levels of ESR1 (Figure
5J-K), whereas bone metastasis was associated with
SNAI2 for tumors expressing ESR1 at either low or high
levels (Figure 5L), suggesting weaker control of SNAI2
by ERa in bone-seeking tumors. Consequently, the
combination of low ESR1 and high SNAI2 expression
was predominant within lung and brain-seeking tumors
(Figure 5O-P), whereas bone-seeking tumors were
mostly those expressing both ESR1 and SNAI2 at high
levels (Figure 5Q). Consistent with these observations,
the negative correlation between ESR1 and SNAI2
expression was weaker in bone compared to lung-seek-
ing tumors (Figure 5R-U; brain-seeking tumors were not
analyzed because only eight of them were ER-positive).
Finally, we investigated Runx2, SNAI2 and ESR1 gene
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Page 9 of 13expression in 58 BCa tumors derived from metastatic
sites: 16 from bone, 19 from brain, 18 from lung and 5
from liver [9]. The standardized signal intensities plot
showed preferential upregulation of Runx2, SNAI2 and
ESR1 in the bone-derived biopsies (Figure 5V). The
unusual concomitant high expression of ESR1 and
Runx2/SNAI2 may reflect dominant regulation of
Runx2/SNAI2 by E2-resistant signaling pathways that
promote BCa bone metastasis.
Discussion
Apart from promoting BCa progression, estrogen signal-
ing has paradoxical anti-metastatic properties
[15,17,19-21]. Potentially contributing to this, E2 antago-
nized the transcription factor Runx2, whose role in
metastasis is being increasingly recognized [22,24,30-32].
Specifically, Runx2 promoted EMT and invasion of BCa
cells in vitro, and this was antagonized by E2 (Figure 2).
At the center stage of the opposing effects of Runx2 and
E2 signaling on EMT and invasion was the transcription
factor SNAI2. Consistent with previous reports
[30,48,49], SNAI2 was stimulated by Runx2 and inhibited
by E2 (Figure 1A and 2A); Runx2 no longer enhanced
EMT and invasion after SNAI2 knockdown; SNAI2
expression in BCa biopsies positively correlated with a
metagene that reports on Runx2 activity and negatively
correlated with ERa mRNA (Figure 1B), and expression
of SNAI2 was associated with BCa metastasis in general
and bone metastasis in particular (Figure 5A-D).
SNAI2 likely plays different roles during various stages
of BCa progression, and its ability to transcriptionally
repress E-cadherin and induce EMT is well documented
[3-5,49-51]. The role of SNAI2 downstream of Runx2 in
BCa is reminiscent of the role of its homologue, SNAI1,
in EMT and metastasis of breast, ovarian, colon, lung
and squamous cell carcinomas [4]. However, SNAI1 is
not stimulated by Runx2 in either MCF7 BCa [34] or
C4-2B PCa cells [30]. Instead, it is SNAI2 that is
strongly stimulated by Runx2 in BCa and PCa cells (Fig-
ure 2). Furthermore, SNAI2 and not SNAI1 was
repressed by E2 in our study (data not shown), and
S N A I 2a n dn o tS N A I 1e x h i b i t e da ni n v e r s ec o r r e l a t i o n
with ERa and E-cadherin in human BCa tumors [49].
Like Runx2, Twist1 has recently been shown to induce
SNAI2 expression, and SNAI2 was essential for Twist1-
mediated EMT of human mammary epithelial cells [50].
Thus, depending on context, either SNAI1 or SNAI2
regulate BCa metastasis, with the latter mediating the
pro-metastatic activity of Runx2 and Twist1 as well as
the anti-metastatic activity of E2.
It remains to be investigated whether Runx2 directly
regulates SNAI2 transcription. On the one hand, there
are several Runx-binding motifs upstream of the SNAI2
transcription start site (Additional file 3: Supplemental
Figure 1A). However, Runx2 ChIP-seq analysis in C4-2B
cells, where SNAI2 expression is also stimulated by
Runx2 (Figure 1B), did not suggest occupancy of Runx2
at these SNAI2 upstream Runx motifs [52]. Instead, we
believe that Runx2 indirectly stimulates SNAI2 expres-
sion via modulation of ETS signaling. This hypothesis is
based on the observation that Runx2 down-regulated
expression of SPDEF (Additional file 3: Supplemental
Figure 1B and [30]), a transcriptional inhibitor belonging
to the ETS family, which suppresses tumor progression
and metastasis [53] in part through direct inhibition of
SNAI2 expression [54]. Indeed, our Runx2 ChIP-seq ana-
lysis in C4-2B/Rx2
dox cells [52] demonstrated strong
occupancy of the SPDEF transcription start site by Runx2
(Additional file 3: Supplemental Figure 1C). We are cur-
rently investigating how such Runx2 occupancy represses
SPDEF transcription, and which of the many ETS sites
upstream of the SNAI2 transcription start site (Addi-
tional file 3: Supplemental Figure 1A) mediate its repres-
sion by SPDEF and/or its activation by other members of
the ETS family. Regardless of the precise mechanism by
which Runx2 controls SNAI2, expression of the two is
tightly correlated in BCa tumors (Figure 1D). In fact,
much of the reported association between Runx2 expres-
sion and BCa metastasis [22] is attributable to SNAI2.
Indeed, the results of our independent analysis validating
the association of Runx2 with metastasis (Additional file
4) are remarkably similar to those demonstrating the
association of SNAI2 with metastasis (Figure 5).
The anti-Runx2/SNAI2, anti-metastatic properties of
E2 signaling in BCa cells may be relevant for early in
vivo metastatic events (Figure 5E), and possibly to tar-
geting BCa metastasis to non-osseous tissues (Figure 5F-
G). However, they appear less relevant for bone
have not relapsed (M) or metastasized to any tissue (N), to brain (O), to lung (P), or to bone (Q). (R) Expression of SNAI2 mRNA in lung-seeking
tumors expressing ESR1/ERa at high versus low levels. The difference is significant (*, P < 0.05) based on unpaired t-test with Welch correction
of the log2-transformed signal intensities. (S) Expression of SNAI2 mRNA in bone-seeking tumors expressing ESR1/ERa at high versus low levels.
The difference is insignificant (NS, P = 0.23) based on unpaired t-test with Welch correction of the log2-transformed signal intensities. (T-U)
Correlation between SNAI2 mRNA and ESR1/ERa mRNA in lung-seeking (T) and bone-seeking (U) tumors with high ERa. Values represent log2
transformed normalized signal intensities. (V) Standardized intensity plot of RUNX2, SNAI2 and ESR1/ERa gene expressions in 58 human BCa
metastases. Expression data of metastatic tissues was extracted from the GEO dataset GSE14020 [9]. BCa, breast cancer; ESR1/ER, estrogen
receptor alpha; GEO, Gene Expression Omnibus; RUNX2, runt related transcription factor 2; SNAI2, snail homolog 2.
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Page 10 of 13metastasis. Whereas SNAI2 expression is associated with
bone-seeking primary BCa tumors and BCa bone metas-
t a s i se v e nm o r es t r o n g l yt h a nw i t hl u n go rb r a i nm e t a s -
tasis, ERa is negatively associated with only non-osseous
metastasis (Figure 5). In fact, consistent with previous
reports [9,55], the correlation between ERa expression
and bone metastasis was positive, not negative in our
cohort (Figure 5H); BCa tumors that metastasized to
bone were mostly ER-positive (Figure 5Q) and BCa
bone metastases co-expressed high levels of Runx2/
SNAI2 and ERa (Figure 5V). The bone-seeking property
that ERa bestows on BCa cells may be counteracted
during the first two years after surgery by the general
anti-metastatic property of estrogens, resulting in a total
neutral effect, but at the end it is the former that pre-
vails (Figure 5H). Possibly, activation of bone-seeking
pathways in primary BCa cells, such as Src1 [8,9], results
in the stimulation of SNAI2 and other Runx2-regulated
genes despite high levels of ERa.
Conclusions
Runx2 stimulates EMT and invasiveness in MCF7 BCa
cell cultures, adding to the mounting evidence for its
role in metastasis. Our data suggest that E2 attenuates
BCa metastasis by antagonizing Runx2. Indeed, EMT
and invasiveness of MCF7 cells were severely compro-
mised by E2 specifically after induction of Runx2. The
linkage between the pro- and anti-metastatic properties
of Runx2 and E2, respectively, is attributable in part to
SNAI2, which is upregulated by Runx2 and downregu-
lated by E2. Furthermore, we observe a strong positive
association between Runx2 and SNAI2 expression, a
negative association between ESR1 and SNAI2, and a
positive correlation between SNAI2 expression and
metastasis in BCa tumors. These observations are con-
sistent with the hypothesis that unopposed stimulation
of Runx2 target genes such as SNAI2 in ER-negative
tumors contributes to their aggressive metastatic pheno-
type. However, the relationship between ER expression
and metastasis is more complicated in bone-seeking
tumors. Here, the negative correlation between SNAI2
and ER is weak, and the anti-metastatic property of ER
is likely masked by an opposite property, which ulti-
mately prevails. Mimicking ER signaling to specifically
antagonize Runx2 and SNAI2 offers a research avenue
towards the development of novel therapeutic
approaches for the management of BCa patients who
fail first line therapy.
Additional material
Additional file 1: Oligonucleotide sequences used in this study. List
of primer pair sequences for qRT-PCR and shRNA sequences.
Additional file 2: The complete list of the ‘common’ genes. The
complete list of the ‘common’ genes, independently regulated by Runx2
and E2 in MCF7/Rx2
dox cells are depicted along with respective fold
changes and p values.
Additional file 3: Potential Mechanisms Linking Runx2 to SNAI2.
Based on the observation that Runx2 down-regulated expression of
SPDEF and strong occupancy of the SPDEF transcription start site by
Runx2 we hypothesize that Runx2 indirectly stimulates SNAI2 expression
in part via modulation of ETS signaling.
Additional file 4: Association of Runx2 activity with metastasis.
Runx2 activity was associated with both osseous and non-osseous
metastases. Bone-seeking BCa tumors exhibit an unusual combination of
high RUNX2 activity and high ERa levels.
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